MacroGenics
MGNX
#8652
Rank
โ‚น22.62 B
Marketcap
โ‚น355.90
Share price
-7.73%
Change (1 day)
146.36%
Change (1 year)

Revenue for MacroGenics (MGNX)

Revenue in 2026 (TTM): โ‚น14.02 Billion

According to MacroGenics's latest financial reports the company's current revenue (TTM ) is โ‚น15.10 Billion. In 2025 the company made a revenue of โ‚น13.42 Billion an increase over the revenue in the year 2024 that were of โ‚น12.72 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for MacroGenics from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น14.02 B4.47%
2025 โ‚น13.42 B5.46%
2024 โ‚น12.72 B167.27%
2023 โ‚น4.76 B-61.54%
2022 โ‚น12.37 B118.5%
2021 โ‚น5.66 B-20.76%
2020 โ‚น7.14 B61.65%
2019 โ‚น4.42 B7.86%
2018 โ‚น4.10 B-58.7%
2017 โ‚น9.92 B68.77%
2016 โ‚น5.88 B-10.9%
2015 โ‚น6.60 B120.45%
2014 โ‚น2.99 B-14.57%
2013 โ‚น3.50 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
โ‚น6.090 T 40,206.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚น6.949 T 45,894.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น3.580 T 23,594.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
โ‚น2.860 T 18,828.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚น6.326 T 41,768.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น4.663 T 30,764.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Xencor
XNCR
โ‚น9.36 B-38.02%๐Ÿ‡บ๐Ÿ‡ธ USA